In despite of which mechanisms, NVP-BEZ235, as a dual PI3K and mTOR inhibitor, strongly inhibited the activation of AKT and mTORC1 pathways by CDDP, which synergized CDDP sensitivity of NPC treatment. Here, AKT1 is linked to nasopharyngeal carcinoma.